<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03742986</url>
  </required_header>
  <id_info>
    <org_study_id>17-00890</org_study_id>
    <nct_id>NCT03742986</nct_id>
  </id_info>
  <brief_title>Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)</brief_title>
  <official_title>Phase II Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study of efficacy of nivolumab with neoadjuvant chemotherapy in patients with IBC
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether the addition of nivolumab to chemotherapy
      improves pathologic complete response (pCR) in the breast and post-therapy lymph nodes
      evaluated histologically (ypT0/Tis ypN0) in patients with inflammatory breast cancer (IBC).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2019</start_date>
  <completion_date type="Anticipated">June 2025</completion_date>
  <primary_completion_date type="Anticipated">June 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in pathological complete response (pCR)</measure>
    <time_frame>6 Years</time_frame>
    <description>pCR is defined as no histologic evidence of invasive tumor cells in the surgical breast specimen, axillary nodes, or sentinel node identified after neoadjuvant chemotherapy (ypT0/Tis ypN0).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">52</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>HER2-negative, including TNBC or HR-positive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2-positive, independent of HR status</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 360mg</intervention_name>
    <description>Nivolumab 360 mg IV on Day 1 of every 21 day cycle (Cycle 1-4)</description>
    <arm_group_label>HER2-negative, including TNBC or HR-positive</arm_group_label>
    <arm_group_label>HER2-positive, independent of HR status</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel 80mg/m^2</intervention_name>
    <description>Paclitaxel 80mg/m^2 IV on Day of 1, 8, 15 of every 21 day cycle (Cycle 1-4)</description>
    <arm_group_label>HER2-negative, including TNBC or HR-positive</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin 60mg/m^2</intervention_name>
    <description>Doxorubicin 60 mg/m^2 IV on Day 1 of every 14 day cycle (Cycle 5-8)</description>
    <arm_group_label>HER2-negative, including TNBC or HR-positive</arm_group_label>
    <arm_group_label>HER2-positive, independent of HR status</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide 600mg/m^2</intervention_name>
    <description>Cyclophosphamide 600mg/m^2 on Day 1 of every 14 day cycle (Cycle 5-8)</description>
    <arm_group_label>HER2-negative, including TNBC or HR-positive</arm_group_label>
    <arm_group_label>HER2-positive, independent of HR status</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2</intervention_name>
    <description>Paclitaxel 80mg/m^2 on Day 1, 8, 15 of every 21 day cycle (Cycle 1-4) OR Docetaxel 75mg/m^2 on Day 1 of every 21 day cycle (Cycle 1-4)</description>
    <arm_group_label>HER2-positive, independent of HR status</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trastuzumab 8mg/kg and 6 mg/kg</intervention_name>
    <description>Trastuzumab 8mg/kg IV on Day 1 of Cycle 1 and then 6mg/kg IV on Day 1 of Cycle 2-4</description>
    <arm_group_label>HER2-positive, independent of HR status</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pertuzumab 840mg and 420mg</intervention_name>
    <description>Pertuzumab 840mg on Day 1 of Cycle 1 and then 420mg IV on Day 1 of Cycle 2-4</description>
    <arm_group_label>HER2-positive, independent of HR status</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed inflammatory breast cancer without distant metastases and have not
             received prior chemotherapy or immunotherapy. All breast cancer subtypes are allowed:
             Triple negative breast cancer (TNBC); Hormone receptor (HR)-positive and human
             epidermal growth factor receptor 2 (HER2)-negative; HR-positive or HR-negative and
             HER2-positive

        Exclusion Criteria:

          -  Clinical or radiologic evidence of distant metastases

          -  Malignancy that progressed within the last five years.

          -  Cardiac disease (history of and/or active disease)

          -  HIV positive

          -  Neuropathy ≥ Grade 2, per the NCI CTCAE v5.0

          -  Allogeneic stem cell or solid organ transplantation

          -  Autoimmune disease where in the opinion of the Investigator would preclude the use of
             immunotherapy

          -  Idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans),
             or evidence of active pneumonitis

          -  Tuberculosis

          -  Pregnancy or lactation

          -  Treatment with CD137 agonists or immune checkpoint−blockade therapies, including
             anti-CD40, anti−CTLA-4, anti−PD-1, and anti−PD-L1 therapeutic antibodies

          -  Treatment with systemic immunosuppressive medications

          -  Cardiopulmonary dysfunction

          -  Clinically significant history of liver disease, including cirrhosis, autoimmune
             hepatic disorders, HIV infection, or active Hepatitis B or Hepatitis C

          -  Subject is pregnant or nursing

          -  Known hypersensitivity to the components of the study drugs(s)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maryann Kwa</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maryann Kwa</last_name>
    <phone>(212) 731-6364</phone>
    <email>maryann.kwa@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fraustina Hsu</last_name>
      <phone>646-754-7124</phone>
      <email>Fraustina.Hsu@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Maryann Kwa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>November 14, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Pertuzumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Immediately following publication. No end date.</ipd_time_frame>
    <ipd_access_criteria>Data will be available as specified in publication</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

